Login / Signup

Salicylate enhances the response of prostate cancer to radiotherapy.

Lindsay A BroadfieldKatarina MarcinkoEvangelia TsakiridisPanayiotis G ZacharidisLinda VillaniJames S V LallyGabe MenjolianDanitra MaharajTammy MathurinMarcia SmokeThomas FarrellPaola MutiGregory R SteinbergTheodoros Tsakiridis
Published in: The Prostate (2019)
Our results show that SAL can enhance RT responses in PrCa. Salsalate is a promising agent to investigate this concept in prospective clinical trials of PrCa in combination with RT.
Keyphrases
  • prostate cancer
  • clinical trial
  • radical prostatectomy
  • early stage
  • locally advanced
  • radiation therapy
  • radiation induced
  • squamous cell carcinoma
  • rectal cancer
  • study protocol